Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to identify the dose of linagliptin in paediatric
patients.
Other efficacy objectives include the comparison of the lowering effect of linagliptin low
dose, high dose and placebo on the fasting plasma glucose (FPG) observed after 12 wk of
treatment.
Furthermore, the study will investigate the pharmacokinetics (PK), the pharmacodynamics (PD)
and the PK/PD relationship of linagliptin in the paediatric population.